Investment Analysts’ Weekly Ratings Updates for ArriVent BioPharma (AVBP)
by Mitch Edgeman · The Markets DailyA number of research firms have changed their ratings and price targets for ArriVent BioPharma (NASDAQ: AVBP):
- 12/22/2025 – ArriVent BioPharma is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating on the stock.
- 12/10/2025 – ArriVent BioPharma is now covered by analysts at BTIG Research. They set a “buy” rating and a $45.00 price target on the stock.
- 12/10/2025 – ArriVent BioPharma is now covered by analysts at BTIG Research. They set a “buy” rating and a $45.00 price target on the stock.
- 12/5/2025 – ArriVent BioPharma was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating.
- 11/25/2025 – ArriVent BioPharma is now covered by analysts at Truist Financial Corporation. They set a “buy” rating and a $43.00 price target on the stock.
- 11/25/2025 – ArriVent BioPharma is now covered by analysts at Truist Financial Corporation. They set a “buy” rating and a $43.00 price target on the stock.
- 11/11/2025 – ArriVent BioPharma had its price target lowered by analysts at Citigroup Inc. from $33.00 to $31.00. They now have a “buy” rating on the stock.
ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.